Toll Free: 1-888-928-9744

Cryptococcosis - Pipeline Review, H1 2017

Published: Mar, 2017 | Pages: 31 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cryptococcosis - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cryptococcosis - Pipeline Review, H1 2017, provides an overview of the Cryptococcosis (Infectious Disease) pipeline landscape.

Cryptococcosis is infection caused by Cryptococcus neoformans fungus. Symptoms include cough, fatigue, fever, head ache, nausea and skin rashes. Predisposing factors are most often seen in people with a weakened immune system, such as those with HIV infection, taking high doses of corticosteroid medications, cancer chemotherapy, or who have Hodgkin's disease. Treatment includes anti fungal drugs. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cryptococcosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cryptococcosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cryptococcosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cryptococcosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Cryptococcosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cryptococcosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Cryptococcosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cryptococcosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cryptococcosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Cryptococcosis (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cryptococcosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cryptococcosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Cryptococcosis - Overview Cryptococcosis - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Cryptococcosis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Cryptococcosis - Companies Involved in Therapeutics Development Arno Therapeutics Inc Visterra Inc Cryptococcosis - Drug Profiles AR-12 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule for Fungal Infections - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Fungal Infections - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target Glucosylceramide for Fungal Infections - Drug Profile Product Description Mechanism Of Action R&D Progress VIS-FNG - Drug Profile Product Description Mechanism Of Action R&D Progress Cryptococcosis - Dormant Projects Cryptococcosis - Product Development Milestones Featured News & Press Releases Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015 May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12 Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Cryptococcosis, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Cryptococcosis - Pipeline by Arno Therapeutics Inc, H1 2017 Cryptococcosis - Pipeline by Visterra Inc, H1 2017 Cryptococcosis - Dormant Projects, H1 2017



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify